Pharmacogenomics Market Research Report – Forecast Till 2027

Pharmacogenomics Market Research Report, By Technology (Microarray, Sequencing, Polymerase Chain Reaction) By Application (Cardiology, Neurological Disorders) By End Users (Hospitals, Research Organizations, Academic Institute)-Forecast till 2027

ID: MRFR/LS/0671-HCR | September 2022 | Region: Global | 90 Pages         

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Pharmacogenomics Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Pharmacogenomics Market: Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Pharmacogenomics Market Size Estimation

Chapter 4. Pharmacogenomics Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Pharmacogenomics Market Factor Analysis

5.1 Porters Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Pharmacogenomics Market, by Technology

6.1 Introduction

6.2 Microarray

Market Estimates & Forecast, 2020-2025

6.3 Sequencing

Market Estimates & Forecast, 2020-2025

6.3.1 Sanger Sequencing

6.3.2 Pyrosequencing

6.3.3 Next-Generation Sequencing

6.3.4 Others

6.4 Polymerase Chain Reaction

Market Estimates & Forecast, 2020-2025

6.5 Others

Chapter 7. Global Pharmacogenomics Market, by Application

7.1 Introduction

7.2 Oncology

Market Estimates & Forecast, 2020-2025

7.2.1 Breast Cancer

7.2.2 Lung Cancer

7.2.3 Others

7.3 Cardiology

Market Estimates & Forecast, 2020-2025

7.4 Neurological Disorders

Market Estimates & Forecast, 2020-2025

7.5 Others

Market Estimates & Forecast, 2020-2025

Chapter 8 Global Pharmacogenomics Market, by End User

8.1 Introduction

8.2 Hospitals and clinics

Market Estimates & Forecast, 2020-2025

8.3 Research Organizations

Market Estimates & Forecast, 2020-2025

8.4 Academic Institute

Market Estimates & Forecast, 2020-2025

8.5 Others

Market Estimates & Forecast, 2020-2025

Chapter 9. Global Pharmacogenomics Market, by Region

9.1 Introduction

9.2 America

9.2.1 North America

9.2.1.1 US

9.2.1.1 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 UK

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia Pacific

9.5 The Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of the Middle East & Africa

Chapter 10 Company Landscape: Pharmacogenomics Market

10.1 Introduction

10.2 Pharmacogenomics Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

Chapter 11 Company Profiles

11.1 Myriad Genetics, Inc.

11.1.1 Company Overview

11.1.2 Product Overview

11.1.3 Financials

11.1.4 Key Developments

11.1.5 SWOT Analysis

11.2 23andMe, Inc.

11.2.1 Company Overview

11.2.2 Product Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Pathway Genomics

11.3.1 Company Overview

11.3.2 Product Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 GeneTech

11.4.1 Company Overview

11.4.2 Product/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 GeneDx.

11.5.1 Overview

11.5.2 Company Overview

11.5.3 Product Overview

11.5.4 Financial overview

11.5.5 Key Developments

11.6 Future Science Group

11.6.1 Overview

11.6.2 Company Overview

11.6.3 Product Overview

11.6.4 Financial Overview

11.6.5 Key Developments

11.7 Teva Pharmaceutical Industries Ltd.

11.7.1 Overview

11.7.2 Product Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Assurex Health, Inc.

11.8.1 Overview

11.8.2 Product Overview

11.8.3 Financials

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.9 Others

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s View Point

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Prediction of Pharmaceutical industry

Chapter 13 Appendix

LIST OF TABLES

Table 1 Pharmacogenomics Industry Synopsis, 2020-2025

Table 2 Global Pharmacogenomics Market Estimates and Forecast, 2020-2025, (USD Million)

Table 3 Global Pharmacogenomics Market by Region, 2020-2025, (USD Million)

Table 4 Global Pharmacogenomics Market by Technology, 2020-2025, (USD Million)

Table 5 Global Pharmacogenomics Market by Application, 2020-2025, (USD Million)

Table 6 Global Pharmacogenomics Market by End Users, 2020-2025, (USD Million)

Table 7 North America Pharmacogenomics Market by Technology, 2020-2025, (USD Million)

Table 8 North America Pharmacogenomics Market by Application, 2020-2025, (USD Million)

Table 9 North America Pharmacogenomics Market by End Users, 2020-2025, (USD Million)

Table 10 US Pharmacogenomics Market by Technology, 2020-2025, (USD Million)

Table 11 US Pharmacogenomics Market by Application, 2020-2025, (USD Million)

Table 12 US Pharmacogenomics Market by End Users, 2020-2025, (USD Million)

Table 13 Canada Pharmacogenomics Market by Technology, 2020-2025, (USD Million)

Table 14 Canada Pharmacogenomics Market by Application, 2020-2025, (USD Million)

Table 15 Canada Pharmacogenomics Market by End Users, 2020-2025, (USD Million)

Table 16 South America Pharmacogenomics Market by Technology, 2020-2025, (USD Million)

Table 17 South America Pharmacogenomics Market by Application, 2020-2025, (USD Million)

Table 18 South America Pharmacogenomics Market by End Users, 2020-2025, (USD Million)

Table 19 Europe Pharmacogenomics Market by Technology, 2020-2025, (USD Million)

Table 20 Europe Pharmacogenomics Market by Application, 2020-2025, (USD Million)

Table 21 Europe Pharmacogenomics Market by End Users, 2020-2025, (USD Million)

Table 22 Western Europe Pharmacogenomics Market by Technology, 2020-2025, (USD Million)

Table 23 Western Europe Pharmacogenomics Market by Application, 2020-2025, (USD Million)

Table 24 Western Europe Pharmacogenomics Market by End Users, 2020-2025, (USD Million)

Table 25 Eastern Europe Pharmacogenomics Market by Technology, 2020-2025, (USD Million)

Table 26 Eastern Europe Pharmacogenomics Market by Application, 2020-2025, (USD Million)

Table 27 Eastern Europe Pharmacogenomics Market by End Users, 2020-2025, (USD Million)

Table 28 Asia Pacific Pharmacogenomics Market by Technology, 2020-2025, (USD Million)

Table 29 Asia Pacific Pharmacogenomics Market by Application, 2020-2025, (USD Million)

Table 30 Asia Pacific Pharmacogenomics Market by End Users, 2020-2025, (USD Million)

Table 31 Middle East & Africa Pharmacogenomics Market by Technology, 2020-2025, (USD Million)

Table 32 Middle East & Africa Pharmacogenomics Market by Application, 2020-2025, (USD Million)

Table 33 Middle East & Africa Pharmacogenomics Market by End Users, 2020-2025, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Pharmacogenomics Market

Figure 3 Segmentation Market Dynamics for Global Pharmacogenomics Market

Figure 4 Global Pharmacogenomics Market Share, by Technology 2020

Figure 5 Global Pharmacogenomics Market Share, by Application 2020

Figure 6 Global Pharmacogenomics Market Share, by End Users, 2020

Figure 7 Global Pharmacogenomics Market Share, by Region, 2020

Figure 8 North America Pharmacogenomics Market Share, by Country, 2020

Figure 9 Europe Pharmacogenomics Market Share, by Country, 2020

Figure 10 Asia Pacific Pharmacogenomics Market Share, by Country, 2020

Figure 11 Middle East & Africa Pharmacogenomics Market Share, by Country, 2020

Figure 12 Global Pharmacogenomics Market: Company Share Analysis, 2020 (%)

Figure 14 Myriad Genetics, Inc.: Key Financials

Figure 15 Myriad Genetics, Inc.: Segmental Revenue

Figure 16 Myriad Genetics, Inc.: Geographical Revenue

Figure 17 23andMe, Inc.: Key Financials

Figure 18 23andMe, Inc.: Segmental Revenue

Figure 19 23andMe, Inc.: Geographical Revenue

Figure 20 Pathway Genomics: Key Financials

Figure 21 Pathway Genomics: Segmental Revenue

Figure 22 Pathway Genomics: Geographical Revenue

Figure 23 GeneTech: Key Financials

Figure 24 GeneTech: Segmental Revenue

Figure 25 GeneTech: Geographical Revenue

Figure 26 GeneDx. : Key Financials

Figure 27 GeneDx. : Segmental Revenue

Figure 28 GeneDx. : Geographical Revenue

Figure 29 Future Science Group: Key Financials

Figure 30 Future Science Group: Segmental Revenue

Figure 31 Future Science Group: Geographical Revenue

Figure 32 Teva Pharmaceutical Industries Ltd.: Key Financial

Figure 33 Teva Pharmaceutical Industries Ltd.: Segmental Revenue

Figure 34 Teva Pharmaceutical Industries Ltd.: Geographical Revenue

Figure 35 Assurex Health, Inc..: Key Financials

Figure 36 Assurex Health, Inc.: Segmental Revenue

Figure 37 Assurex Health, Inc.: Geographical Revenue

Pharmacogenomics Market Speak to Analyst Request a Free Sample

Pharmacogenomics Market Overview


The Pharmacogenomics Market will acquire a CAGR of 8.8 % and a significant value in the forecast period b 2027.


Pharmacogenomics is a component of genomic medicine used in medical treatment. The market focuses on developing precision medicine to improve drug efficacy and safety. The developing methods to determine drug dosages, vaccines, and reduction of overall healthcare costs are boosting the market.


The major growth factors such as the product approvals, growth of inorganic strategies, and demand for precision medicine are accelerating the market. The rise in the elderly population demands proper and effective medication. The growing adoption of pharmacogenomics procedures in the healthcare sector and the awareness among the patient population due to its personalised therapy are driving the market. The huge number of severe chronic diseases like HIV, cancer, tuberculosis, and others, is accelerating the pharmacogenomics market. The advancements integrated with molecular diagnostics procedures will boost the market growth in the forecast period.


The healthcare professionals are skilled and trained to perform the pharmacogenomics diagnostics test. The key player’s developments to improve pharmacogenomics are aiding the market. The research and development activities and the disposable income propel towards higher growth opportunities for the market.


COVID 19 Analysis of Pharmacogenomics Market


People across the globe are being affected by Coronavirus, the global pandemic. It has negatively impacted the operations of all the industries, except for the pharmaceutical industry. There has been a complete lockdown situation in almost every part of the world and people are forced to stay at their homes. Every nation has sealed their borders which mean no international travel will be possible shortly. The businesses are also being shut down. Many people were laid off from their workplaces. This has affected the Pharmacogenomics Industry as well.


It is being anticipated that post the covid19 situation, global pharmacogenomics market share will grow tremendously. It has made a prominent advance in the field of medicine from its reaction to prevention as it involves both pharmacology and genomics. While developing a vaccine for the coronavirus a large number of people underwent highly specialized clinical trials to checks its positive and negative responses. Based on the results dosage was fixed. This was all possible because of altering and tailoring the medicinal treatment.


Pharmacogenomics Market Dynamics


Drivers


Precision medicines have proved to be efficient for the treatment of cancer. For the development of such drugs pharmacogenomics and related expertise are required. These specially developed medicines have reduced the medical costs for patients who have been spending a large amount of money on responsive treatments.


Opportunities


There is a need to enhance the drug efficacy and security over a while. The increase in the rate of adverse reactions to various drugs and large investment in the related research & development projects has prompted the global pharmacogenomics market growth. 


Restraints


The cost of carrying on the research & development projects in the field of pharmacogenomics is very high. The rate of failure of projects is also high which is hindering the growth of its global market. Medical and research institutes require high-tech laboratories to carry out such operations. There is also a lack of awareness among the general public about precision medicine. 


Value Chain Analysis


More and more people are adopting precision medicine in the current scenario. This has boosted the Pharmacogenomics industry. Precision medicines are developed to meet the accurate needs of individual patients. These combine the genetic and environmental factors to create a drug for a specific disease. Efficient treatment and procedures to reduce the side effects of the medicines are watched closely to improve its results. This requires the studies of drugs as well as their reaction to patient’s genetics and disorders. With its help, many important discoveries have been made in the field of cancer and its treatment.


Figure 1:- Pharmacogenomics market share, by region Pharmacogenomics Market


Sources: WHO, annual reports, press release, white paper, and company presentation


Pharmacogenomics Market Segmentation


According to the global pharmacogenomics market analysis, its market can be divided into various segments. These are based on technology, based on application, and based on end-users


Based on technology


Based on technology the field of pharmacogenomics market is further segmented into DNA Sequencing, Microarray, Polymerase Chain Reaction, Mass Spectrometry, Electrophoresis, and many Other Technologies. DNA sequencing can be of various types such as Sanger sequencing, next-generation sequencing, pyro-sequencing, and many others.


Polymerase Chain Reaction based pharmacogenomics activities are expected to hold the largest pharmacogenomics market share throughout the period under forecast.


Based on Application


Pharmacogenomics and its methods can be applied to various fields such as Drug Discovery, Neurology, Pain Management, Oncology, and others.


Based on End-users


Various end-users of this industry are Healthcare providers, government and other Research & development institutes, academic medical institutions, and healthcare consumers.


Pharmacogenomics Market Regional Analysis


The global pharmacogenomics market is increasing rapidly. It is leaving a huge impression in every part of the world owing to its specialization and advancements. The regions of the operation of its global market include regions of america, europe, asia-pacific, and the rest of the world.


American region, which includes the area of North America (the US and Canada) and Latin America, provides the largest market for Pharmacogenomics Industry. This owns to a large number of investments in medicinal study and research. The level of awareness among the general public is also very high.2016, according to the Centres for Diseases Control and Prevention in the U.S., heart disease was the leading cause of death for both men and women. Moreover, it was also estimated that the healthcare expenditure for heart diseases in the U.S. reaches USD 200 billion each year.


The European region, which includes Germany, UK, France, Russia, and Italy, is also expanding and holds the second-largest market share of its global pharmacogenomics market. There is a large population of people suffering from cardiovascular and other diseases. This is raising the demand for precision medicines.


Asia-Pacific (ASPAC) region, which includes China, Japan, India, Australia, and South Korea, is growing tremendously throughout the forecasted period. The developing countries, such as India, are providing a cheaper infrastructure for research & development projects.According to the Indian Brand Equity Foundation in 2016, the Indian biotech industry is estimated to reach USD 100 billion by 2025 from USD 7 billion in 2015 with a CAGR of 30.46%.


The rest of the world region, which includes the region of the Middle East and Africa, is growing at a slower but constant rate owing to the lower technological development, low per capita health care expenditure, and fewer government initiatives.


Pharmacogenomics Market Competitive Landscape


The list of major global pharmacogenomics market key players is as follows:



  • Myriad Genetics, Inc. (U.S.)

  • 23andMe, Inc. (U.S.)

  • Pathway Genomics (U.S.)

  • GeneTech (U.S.)

  • (the U.S.)

  • Future Science Group (U.S.)

  • Teva Pharmaceutical Industries Ltd. (Israel)

  • Assurex Health, Inc. (U.S.)

  • Bristol-Myers Squibb Company

  • Hoffmann-La Roche Ltd.

  • Merck & Co., Inc.

  • Johnson & Johnson

  • Abbott Laboratories, Inc.


These companies form joint ventures or come together in partnerships for certain projects, mergers, and acquisitions to make technological advancements. They strive to develop end-products and services that are unique, cost-effective, and proficient in working and can deliver accurate solutions to the respective problems.


Recent Developments


In November 2021


Agena Bioscience, a world provider of genetic testing solutions, has declared its partnership with Manchester University (MU). The partnership was to expand awareness and provide access to pharmacogenomics educational resources. Manchester University is the leading institution that offers innovative pharmacogenomic educational programs to the healthcare and laboratory sectors. Based on the partnership, Agena Bioscience will offer MU PGx programs to its customers, including a Graduate degree Certificate in PGx and a Master’s degree of Science in PGx.


In May 2020


 Green Shield, a global player and Canada-based company, partnered with GenXys, the pharmacogenomics company. The partnership aimed to develop efficient software to assist in research and develop precise medicines that would produce positive results.


Report Overview


This report about the global pharmacogenomics market trends includes the following elements:



  • Market Overview

  • COVID19 Analysis

  • Market Dynamics

  • Value Chain Analysis

  • Market Segmentation

  • Regional Analysis

  • Competitive Landscape

  • Recent Developments


This research report provides a comprehensive study about the global pharmacogenomics market outlook. it includes a thorough analysis of its market trends and the areas of new advancements. pharmacogenomics is related to the study of human genes and their reaction to specific drugs under given circumstances. It also helps in identifying a person’s vulnerability to certain diseases and developing accurate medicines to cure the disorder. These specialized medicines have reduced the medical costs for people who have been spending a large amount of money on responsive treatments.



Report Scope:

Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   2018-2023: 5.8%
  Base Year   2019
  Forecast Period   2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Technology, Application, And End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Myriad Genetics, Inc. (U.S.), 23andMe, Inc. (U.S.), Pathway Genomics (U.S.), GeneTech (U.S.), GeneDx. (U.S.), Future Science Group (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Assurex Health, Inc. (U.S.)
  Key Market Opportunities

  • Huge patient population
  • Continuously developing economies
  •   Key Market Drivers

  • Prevalence of chronic diseases
  • Expansion of the biotechnology sector


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    pharmacogenomics market is expected to grow at 5.8% CAGR from 2018 to 2023.

    pharmacogenomics market growth is driven by prevalence of chronic diseases and the expansion of the biotechnology sector.

    Lack of consistency in launch of pharmacogenomics products and lack of awareness among patients are challenges faced by the global pharmacogenomics market.

    The Americas are expected to dominate the global pharmacogenomics market due to the large healthcare expenditure and prevalence of various chronic diseases.

    23andMe, Inc., GeneDx, Teva Pharmaceutical Industries Ltd., GeneTech, Myriad Genetics, Inc., Future Science Group, Assurex Health, Inc., and Pathway Genomics are prominent players of the global pharmacogenomics market.